Analysts Offer Insights on Healthcare Companies: Apellis Pharmaceuticals (APLS), Neurocrine (NBIX) and Orchard Therapeutics (ORTX)
TipRanksOct 9, 2023 22:10 ET
Stifel Downgrades Orchard Therapeutics to Hold, Announces $16 Price Target
BenzingaOct 5, 2023 10:36 ET
Orchard Therapeutics Analyst Ratings
BenzingaAug 9, 2023 09:59 ET
Cantor Fitzgerald Reiterates Overweight on Orchard Therapeutics, Maintains $15 Price Target
BenzingaJun 27, 2023 08:18 ET
Oppenheimer Adjusts Orchard Therapeutics Price Target to $34 From $37, Maintains Outperform Rating
MT NewswiresJun 13, 2023 08:54 ET
Cantor Fitzgerald Maintains Overweight on Orchard Therapeutics, Raises Price Target to $15
BenzingaMar 28, 2023 07:07 ET
Oppenheimer Adjusts Orchard Therapeutics Price Target to $37 From $5, Maintains Outperform Rating
MT NewswiresMar 13, 2023 09:17 ET
No Data
No Data